Capstan Medical Secures $110M to Advance Robotic Heart Valve Technology with Pivotal Trials by 2026

Capstan Medical has successfully secured $110 million in a Series C funding round to propel its robotic heart valve technology into pivotal trials by 2026[1][2]. This significant boost was led by venture capital firm Eclipse and saw contributions from existing supporters like Intuitive Ventures, along with new investor Gideon Strategic Partners[1][2]. The funding aims to advance Capstan's innovative mitral valve technology which is scheduled for first-in-human trials by early 2025 and to further develop its treatment solutions for tricuspid valve regurgitation, leveraging its minimally invasive, robotic-assisted system[1]. This strategic investment not only supports the progression toward clinical trials but also facilitates company expansion, positioning Capstan as a front-runner in addressing structural heart diseases with advanced robotic solutions[2].